Head and Neck Cancer Clinical Trial
Official title:
A Randomized Phase II Study of Concomitant Chemoradiotherapy With 5-Fluorouracil/Hydroxyurea Compared to FHX Plus Bevacizumab for Intermediate Stage and Selected Stage IV Cancers of the Head and Neck
The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant chemoradiotherapy regimen of bevacizumab/5-fluorouracil (5-FU)/hydroxyurea/radiation therapy (B-FHX) in comparison to 5-fluorouracil hydroxyurea (FHX) alone.
In this study, we intend to explore the feasibility and the effects of adding bevacizumab to
Fl-TX in patients with intermediate stage head and neck cancer and selected patients with
stage IV disease. As mentioned previously, although single modality therapy (surgery or
radiotherapy alone) is often used to treat patients with Stage II head and neck
malignancies, with substantial success, still there is a sizeable group of patients
(approximately 30% or 40%) who fail these treatments, and represent with locoregional
recurrences which are much more difficult to treat. Furthermore, the common use of radical
surgery in many instances leads to loss of organ function.
Based on this knowledge, we feel that it is justifiable to include stage II patients (T2NO)
in combined chemoradiation studies. Our extensive experience using chemoradiotherapy in
patients with regionally advanced non-metastatic Stage 4 cancers of the head and neck area
suggests that selected patients with low nodal status (Nondisease) including those with T4
primaries (i.e. T4 NO MO and T4 Nl MO) have a lower risk of distant failure than patients
that present with higher nodal status (N2 and N3 disease). Aggressive combined locoregional
therapies such as the one that will be administered in the study, are in our opinion
appropriate for this group of patients as they address the major concern which is
locoregional failure.
The primary goal of the study is exploration of the pharmacodynamic effects of bevacizumab
(10 mg/kg) on appropriate markers of angiogenesis in tumor tissue in comparison to a
non-bevacizumab containing chemoradiation regimen (FHX alone). These results will be
correlated with a number of clinical endpoints including rapidity of clinical response,
locoregional control rates, time to progression, need of salvage surgery, overall survival
and measures of QOL and organ function. The predictive and prognostic value of specific
molecular markers in patients with HNC will also be evaluated. In order to shorten the total
duration of treatment without affecting the total administered dose, we have modified our
traditional radiation schedule in FHX to include two treatment daily fractions as opposed to
one. This modification will allow for the completion of all treatment in 4 to 5 cycles as
opposed to the traditional 6 to 7 cycles. Given this modification in the radiation schedule,
we considered it prudent to include a control arm (modified FHX) in addition to B-FHX,
within a randomized design. The control arm will also help with the interpretation of the
results obtained with the measurement of the correlative markers of angiogenesis.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |